$14.30
1.45% yesterday
Nasdaq, Jun 13, 10:00 pm CET
ISIN
US29772L1089
Symbol
ETON
Sector
Industry

Eton Pharmaceuticals, Inc. Stock price

$14.30
-2.77 16.23% 1M
+1.95 15.79% 6M
+0.98 7.36% YTD
+10.67 293.94% 1Y
+8.80 160.00% 5Y
+8.05 128.80% 10Y
+8.05 128.80% 20Y
Nasdaq, Closing price Fri, Jun 13 2025
-0.21 1.45%
ISIN
US29772L1089
Symbol
ETON
Sector
Industry

Key metrics

Market capitalization $383.49m
Enterprise Value $396.06m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 8.19
P/S ratio (TTM) P/S ratio 7.93
P/B ratio (TTM) P/B ratio 15.68
Revenue growth (TTM) Revenue growth 40.86%
Revenue (TTM) Revenue $48.33m
EBIT (operating result TTM) EBIT $-2.27m
Free Cash Flow (TTM) Free Cash Flow $-2.61m
Cash position $17.42m
EPS (TTM) EPS $-0.18
P/E forward negative
P/S forward 4.92
EV/Sales forward 5.08
Short interest 3.23%
Show more

Is Eton Pharmaceuticals, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,847 stocks worldwide.

Eton Pharmaceuticals, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

3 Analysts have issued a Eton Pharmaceuticals, Inc. forecast:

3x Buy
100%

Analyst Opinions

3 Analysts have issued a Eton Pharmaceuticals, Inc. forecast:

Buy
100%

Financial data from Eton Pharmaceuticals, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
48 48
41% 41%
100%
- Direct Costs 20 20
73% 73%
42%
28 28
24% 24%
58%
- Selling and Administrative Expenses 26 26
41% 41%
55%
- Research and Development Expense 4.66 4.66
35% 35%
10%
-0.36 -0.36
124% 124%
-1%
- Depreciation and Amortization 1.91 1.91
103% 103%
4%
EBIT (Operating Income) EBIT -2.27 -2.27
523% 523%
-5%
Net Profit -4.58 -4.58
603% 603%
-9%

In millions USD.

Don't miss a Thing! We will send you all news about Eton Pharmaceuticals, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Eton Pharmaceuticals, Inc. Stock News

Positive
Seeking Alpha
8 days ago
Eton Pharmaceuticals is experiencing explosive rare-disease revenue growth, with a 117% YoY increase and a robust pipeline fueling future expansion. Despite a 400% share price surge, ETON remains attractively valued versus peers, offering high growth potential for risk-tolerant investors. Operational leverage is improving, and near-term catalysts—product launches, label expansions, and M&A—coul...
Neutral
GlobeNewsWire
17 days ago
• KHINDIVI is the first and only FDA-approved hydrocortisone oral solution• Commercial launch expected the week of June 2nd • Eton expects combined peak sales of KHINDIVI and ALKINDI SPRINKLE® (hydrocortisone) oral granules to exceed $50 million
Positive
Seeking Alpha
24 days ago
Giant pharma companies are not the right owners of ultra-rare disease orphan drugs. The associated revenue streams are simply too small. ETON can acquire and develop these drugs, better serving patients and investors. The model is already working well. ETON is able to execute on straightforward product improvements, and has the focus to educate specialist doctors on the need for these rare drugs.
More Eton Pharmaceuticals, Inc. News

Company Profile

Eton Pharmaceuticals, Inc. engages in the development and commercialization of prescription drug products. It focuses on product candidates that are liquid in formulation, including injectables, oral liquids and ophthalmics. The company was founded in April 2017 and is headquartered in Deer Park, IL.

Head office United States
CEO Sean Brynjelsen
Employees 31
Founded 2017
Website etonpharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today